Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
NCT07691606Phase 1Recruiting
- Sponsor
- Taiho Oncology
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Countries
- 6
01
Overview
Phase 1, open-label trial of ARC-02 in B-cell non-Hodgkin lymphoma (4 arms), sponsored by Taiho Oncology. Primary endpoints: Dose-Limiting Toxicities up to 5 years, Treatment-Emergent Adverse Events and Serious Adverse Events up to 5 years and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
ARC-02
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07691606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691606.